Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients

Antimicrobial Agents and Chemotherapy
R Brigg TurnerWilliam P Petros

Abstract

The current recommendations for intravenous (i.v.) acyclovir dosing in obese patients suggest using ideal body weight (IBW) rather than total body weight (TBW). To our knowledge, no pharmacokinetic analysis has validated this recommendation. This single-dose pharmacokinetic study was conducted in an inpatient oncology population. Enrollment was conducted by 1:1 matching of obese patients (>190% of IBW) to normal-weight patients (80 to 120% of IBW). All patients received a single dose of i.v. acyclovir, 5 mg/kg, infused over 60 min. Consistent with current recommendations, IBW was used for obese patients and TBW for normal-weight patients. Serial plasma concentrations were obtained and compared. Seven obese and seven normal-weight patients were enrolled, with mean body mass indexes of 45.0 and 22.5 kg/m(2), respectively. Systemic clearance was substantially higher in the obese than normal-weight patients (mean, 19.4 ± 5.3 versus 14.3 ± 5.4 liters/h; P = 0.047). Area under the concentration-time curve was lower in the obese patients (15.2 ± 2.9 versus 24.0 ± 9.4 mg · h/liter; P = 0.011), as was maximum concentration (5.8 ± 0.9 versus 8.2 ± 1.3 mg/liter; P = 0.031). Utilization of IBW for dose calculation of i.v. acyclovir in obes...Continue Reading

Associated Clinical Trials

Oct 25, 2012·Aaron Cumpston, PharmD

References

Jul 20, 1982·The American Journal of Medicine·M R BlumP de Miranda
Mar 1, 1982·Antimicrobial Agents and Chemotherapy·O L LaskinP S Lietman
Apr 1, 1981·Antimicrobial Agents and Chemotherapy·S A SpectorR E Keeney
Dec 20, 2000·Antimicrobial Agents and Chemotherapy·M TodY Aujard
Sep 15, 2001·Antimicrobial Agents and Chemotherapy·E P Acosta, H H Balfour
Sep 24, 2005·Clinical Pharmacokinetics·Sarayut JanmahasatianBruce Green
Jul 28, 2007·Pharmacotherapy·Manjunath P Pai, David T Bearden
Jul 4, 2009·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Jovino Ocasio HernandezGlenn Wysock
Sep 6, 2012·Current Clinical Pharmacology·Federico Pea
Jan 17, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jason A RobertsUNKNOWN DALI Study

❮ Previous
Next ❯

Citations

Apr 27, 2019·Open Forum Infectious Diseases·Katie E BarberKayla R Stover

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

© 2021 Meta ULC. All rights reserved